Vector-mediated Tum-5 expression in neovascular endothelial cells for treating hepatocellular carcinoma

  • Authors:
    • Chun Li
    • Xingang Guan
    • Boqian Sun
    • Mingyao Ma
    • Peng Wang
    • Xiaodong Gai
  • View Affiliations

  • Published online on: February 15, 2017     https://doi.org/10.3892/etm.2017.4127
  • Pages: 1521-1525
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hypervascular hepatocellular carcinoma (HCC) is one of the leading causes of cancer-associated mortality. Angiogenesis is an important contributor to HCC progression and metastasis; therefore, inhibiting angiogenesis may be an effective method of treating HCC. Tumstatin is a novel type of efficient endogenous vascular endothelial cell growth inhibiting factor. The anti‑angiogenic activity of tumstatin is localized to the 54‑132 amino acid region (Tum‑5). In a previous study performed by our group, the gene fragment encoding Tum‑5 was cloned and inserted into a pLXSN retroviral vector. In the present study, the anti‑angiogenic effects of Tum‑5 and the antitumor effects exerted by the pLXSN‑Tum‑5 vector in vivo were investigated. The results demonstrated that pLXSN‑Tum‑5 significantly inhibited the growth of human umbilical vein endothelial cells compared with pLXSN, but had no obvious effect on HepG2 cell growth. Moreover, the antitumor and anti-angiogenic activity of Tum‑5 was examined in vivo using a xenograft of H22 HCC cells. The results indicated that pLXSN-Tum‑5 significantly inhibited tumor growth following 5 injections over 10 days. The size and weight of tumors in the pLXSN‑Tum‑5 group were lower than those in the saline and pLXSN groups. Furthermore, immunohistochemical analysis with CD31 antibodies indicated that the average microvessel density in the pLXSN-Tum-5 group were significantly lower than that in the saline and pLXSN groups. These results suggested that Tum‑5 exerts its antitumor activity by suppressing vascular endothelial cells. The gene fragment of Tum‑5 may be developed as an effective inhibitor of angiogenesis and used to treat patients with HCC.
View Figures
View References

Related Articles

Journal Cover

April-2017
Volume 13 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li C, Guan X, Sun B, Ma M, Wang P and Gai X: Vector-mediated Tum-5 expression in neovascular endothelial cells for treating hepatocellular carcinoma. Exp Ther Med 13: 1521-1525, 2017
APA
Li, C., Guan, X., Sun, B., Ma, M., Wang, P., & Gai, X. (2017). Vector-mediated Tum-5 expression in neovascular endothelial cells for treating hepatocellular carcinoma. Experimental and Therapeutic Medicine, 13, 1521-1525. https://doi.org/10.3892/etm.2017.4127
MLA
Li, C., Guan, X., Sun, B., Ma, M., Wang, P., Gai, X."Vector-mediated Tum-5 expression in neovascular endothelial cells for treating hepatocellular carcinoma". Experimental and Therapeutic Medicine 13.4 (2017): 1521-1525.
Chicago
Li, C., Guan, X., Sun, B., Ma, M., Wang, P., Gai, X."Vector-mediated Tum-5 expression in neovascular endothelial cells for treating hepatocellular carcinoma". Experimental and Therapeutic Medicine 13, no. 4 (2017): 1521-1525. https://doi.org/10.3892/etm.2017.4127